

RECEIVED  
CENTRAL FAX CENTER

JUN 29 2007



Vertex Pharmaceuticals Incorporated  
130 Waverly Street • Cambridge, MA 02139-4242  
Tel. 617.444.6100 • Fax 617.444.6483  
<http://www.vrtx.com>

---

## FAX TRANSMISSION

---

To	USPTO
Examiner	Michael P. Barker
Group Art Unit	1626
From	Michael C. Badia
Date	June 29, 2007
Application No.	10/749,121
Attorney Docket No.	VPI/02-05 US
Total Pages	15

### Message or Comment

If any problems occur with this fax transmittal, please call (617) 444-7517 immediately.

RECEIVED  
CENTRAL FAX CENTER  
JUN 29 2007

Attorney Docket No.: V

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/749,121  
Confirmation No.: 3285  
Filing Date: December 30, 2003  
Examiner: Michael P. Barker  
Group Art Unit: 1626  
Applicants: Jeffrey O. Saunders et al.  
For: SULFHYDANTOINS AS PHOSPHATE ISOSTERES

Certificate of Facsimile Transmission Under 37 CFR §1.8

I hereby certify that this correspondence and any documents referred to as attached hereto are being facsimile transmitted to the United States Patent and Trademark Office on June 29, 2007

  
Lauren DeVincenzo

June 29, 2007  
Cambridge, Massachusetts

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:

Transmitted herewith: ☒ a Reply to Office Action; ☐ a Petition for Extension of Time; ☐ a Declaration; ☐ a Power of Attorney; ☐ a copy of a Notice to File Missing Parts; ☐ a Response to Notice to File Missing Parts; ☐ a Supplemental Declaration; ☐ an Associate Power of Attorney; ☐ a substitute Specification; ☐ formal drawings; ☐ Notice of Appeal; ☐ Appeal Brief; ☐ Petition for Revival; to be filed in the above-identified patent application.

Applicants: Jeffrey O. Saunders et al.  
Application No.: 10/749,121

RECEIVED  
CENTRAL FAX CENTER  
JUN 29 2007


FEE FOR ADDITIONAL CLAIMS

- ☒ A fee for additional claims is not required.
- ☐ A fee for additional claims is required.
- ☐ A check in the amount of \$\_\_\_ in payment of the filing fee is transmitted herewith.
- ☐ Please charge \$\_\_\_ to Deposit Account No. 50-0725 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.
- ☒ The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

MISCELLANEOUS FEES

- ☐ Please charge \$\_\_\_\_\_ to Deposit Account No. 50-0725 in payment of the fee for \_\_\_\_\_ (37 C.F.R. § \_\_\_\_\_).

Respectfully submitted,

  
\_\_\_\_\_  
Michael C. Badia Reg. No. 51,424  
Agent for Applicants  
c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel: (617) 444-6467  
Fax: (617) 444-6483

004/015  
RECEIVED  
CENTRAL FAX CENTER  
JUN 29 2007

Attorney Docket No.: V

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/749,121  
Confirmation No.: 3285  
Filing Date: December 30, 2003  
Examiner: Michael P. Barker  
Group Art Unit: 1626  
Applicants: Jeffrey O. Saunders et al.  
For: SULFHYDANTOINS AS PHOSPHATE ISOSTERES

Certificate of Facsimile Transmission Under 37 CFR §1.8

I hereby certify that this correspondence and any documents referred to as attached hereto are being facsimile transmitted to the United States Patent and Trademark Office on June 29, 2007

  
Lauren DeVincenzo

June 29, 2007  
Cambridge, Massachusetts

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:

Transmitted herewith: ☒ a Reply to Office Action; ☐ a Petition for Extension of Time; ☐ a Declaration; ☐ a Power of Attorney; ☐ a copy of a Notice to File Missing Parts; ☐ a Response to Notice to File Missing Parts; ☐ a Supplemental Declaration; ☐ an Associate Power of Attorney; ☐ a substitute Specification; ☐ formal drawings; ☐ Notice of Appeal; ☐ Appeal Brief; ☐ Petition for Revival; to be filed in the above-identified patent application.

Applicants: Jeffrey O. Saunders et al.  
Application No.: 10/749,121

RECEIVED  
CENTRAL FAX CENTER

JUN 29 2007


FEE FOR ADDITIONAL CLAIMS

- ☒ A fee for additional claims is not required.
- ☐ A fee for additional claims is required.
- ☐ A check in the amount of \$\_\_\_ in payment of the filing fee is transmitted herewith.
- ☐ Please charge \$\_\_\_ to Deposit Account No. 50-0725 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.
- ☒ The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

MISCELLANEOUS FEES

- ☐ Please charge \$\_\_\_\_\_ to Deposit Account No. 50-0725 in payment of the for \_\_\_\_\_ (37 C.F.R. § \_\_\_\_\_).

Respectfully submitted,

  
Michael C. Badia Reg. No. 51,424  
Agent for Applicants  
c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel: (617) 444-6467  
Fax: (617) 444-6483

RECEIVED  
CENTRAL FAX CENTER

JUN 29 2007

VPI/02-05 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Michael P. Barker  
Group Art Unit : 1626  
Applicants : Jeffrey O. Saunders et al.  
Serial No : 10/749,121  
Confirmation No. : 3285  
Filed : December 30, 2003  
For : SULFHYDANTOENS AS PHOSPHATE ISOSTERES

June 29, 2007  
Cambridge, Massachusetts

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

AMENDMENT AND REPLY TO OFFICE ACTION

Sir:

This is in response to the May 29, 2007 Office Communication regarding a non-compliant amendment and the September 12, 2006 Office Communication in the above-identified application. Applicants have responded before the thirty day, June 29, 2007 deadline. Consequently, this Reply is timely filed.

Amendments to the claims begin at page 2 of this Reply.

Remarks begin at page 9 of this Reply.